BioNTech SE ADR [BNTX] stock prices are up 18.05% to $113.10 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BNTX shares have gain 14.61% over the last week, with a monthly amount glided 10.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on May 29, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $110. Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $145. On January 10, 2025, Truist initiated with a Buy rating and assigned a price target of $172 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $170 on December 11, 2024. BMO Capital Markets reiterated its recommendation of a Outperform. Evercore ISI upgraded its rating to Outperform for this stock on November 19, 2024, and upped its price target to $125. In a note dated November 19, 2024, Berenberg initiated an Buy rating and provided a target price of $130 on this stock.
The stock price of BioNTech SE ADR [BNTX] has been fluctuating between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $122 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $113.10 at the most recent close of the market. An investor can expect a potential return of 7.87% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
The BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.97B for trailing twelve months, representing a drop of -5.51%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.04 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 107.60 points at the first support level, and at 102.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 117.29, and for the 2nd resistance point, it is at 121.49.
Ratios To Look Out For
It’s worth pointing out that BioNTech SE ADR [NASDAQ:BNTX]’s Current Ratio is 10.18. As well, the Quick Ratio is 10.02, while the Cash Ratio is 6.64. Considering the valuation of this stock, the price to sales ratio is 9.16, the price to book ratio is 1.33.
Transactions by insiders
Recent insider trading involved ATHOS KG, 10% Owner, that happened on Jun 02 ’25 when 0.17 million shares were purchased. 10% Owner, ATHOS KG completed a deal on May 28 ’25 to buy 0.5 million shares. Meanwhile, Director Jeggle Helmut Wolfgang bought 0.15 million shares on May 07 ’25.
